#AbbVie

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

The evening dose of AbbVie’s hepatitis C treatment Viekira Pak may interact harmfully with HIV protease inhibitors.

Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Gilead has applied to the FDA for approval of the combo tablet of Sovaldi and velpatasvir to treat those with genotypes 1 through 6 of...

The FDA has required AbbVie to change the labels for its two hepatitis C treatments after receiving numerous reports of serious liver...

In recent trials Harvoni, Viekira Pak and grazoprevir/elbasvir all cured high rates of hepatitis C among those coinfected with HIV.

The FDA has approved AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 of hepatitis C virus among...

Once you’ve officially rid yourself of hepatitis C, how certain can you be that the virus is gone for good?

Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...

In December, the U.S. Food and Drug Administration approved AbbVie’s interferon-free hepatitis C virus regimen Viekira Pak to treat people..

Viekira Pak plus ribavirin boasts a hepatitis C cure rate in the low-90 percent range among those with genotype 1 of the virus who are coinfec...

The FDA has approved the combination tablet Prezcobix (darunavir/cobicistat) to treat HIV in combination with other ARVs among both...

Up to 30 percent of people living with HIV in the United States are also living with hep C.